ETOPOPHOS

This brand name is authorized in Australia, Estonia, France, New Zealand, United Kingdom, United States

Active ingredients

The drug ETOPOPHOS contains one active pharmaceutical ingredient (API):

1 Etoposide UNII 528XYJ8L1N - ETOPOSIDE PHOSPHATE

The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA-topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts. Read about Etoposide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ETOPOPHOS Powder for solution for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01CB01	Etoposide	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CB Podophyllotoxin derivatives
Discover more medicines within L01CB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 4428C, 7237X
Country: EE	Ravimiamet	Identifier(s): 1810202, 1852488
Country: FR	Base de données publique des médicaments	Identifier(s): 65619363
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 117778
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 3482, 9537
Country: US	FDA, National Drug Code	Identifier(s): 0015-3404, 61269-410